



Listing of Claims:

1. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier substance and a compound of the formula (I) or (Ia), and/or a pharmaceutically acceptable acid addition salt thereof,



(I)



(Ia)

in which the substituents have the following significance:

R₁: C₁-C₆-alkyl; C₂-C₆-alkenyl; C₂-C₆-alkinyl; C₃-C₁₆-(cyclical saturated group)alkyl, where alkyl is C₁-C₆; C₄-C₁₆-(cyclical saturated group)alkenyl, where alkenyl is C₂-C₆; C₄-C₁₆-(cyclical saturated group)alkinyl, where alkinyl is C₂-C₆; C₇-C₁₆-arylalkyl where aryl is C₆-C₁₀-aryl and alkyl is C₁-C₆-alkyl; C₈-C₁₆-arylalkenyl, where aryl is C₆-C₁₀-aryl and alkenyl is C₂-C₆-alkenyl; C₈-C₁₆-arylalkinyl, where aryl is C₆-C₁₀-aryl and alkinyl is C₂-C₆-alkinyl;

R₂: **benzyl**; C₄-C₆-alkyl; C₂-C₆-alkinyl; C₃-C₁₆-(cyclical saturated group)alkyl, where alkyl is C₁-C₆; C₄-C₁₆-(cyclical saturated group)alkenyl, where alkenyl is C₂-C₆; C₄-C₁₆-(cyclical saturated group)alkinyl, where alkinyl is C₂-C₆; C₈, C₉, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅, or C₁₆-arylalkyl, where

aryl is C₆-C₁₀-aryl and alkyl is C₁-C₆-alkyl; C₈, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅ or C₁₆-arylalkenyl, where aryl is C₆-C₁₀-aryl and alkenyl is C₂-C₆-alkenyl; C₈-C₁₆-arylalkinyl, where aryl is C₆-C₁₀-aryl and alkinyl is C₂-C₆-alkinyl; C₃-C₆-alkinoyl; and C₉-C₁₆-arylalkinoyl, where aryl is C₆-C₁₀-aryl and alkinoyl is C₃-C₆-alkinoyl;

R₃: hydrogen, C₁-C₆-alkyl; C₂-C₆-alkenyl; C₇-C₁₆-arylalkyl, where aryl is C₆-C₁₀-aryl and alkyl is C₁-C₆-alkyl; C₈-C₁₆-arylalkenyl, where aryl is C₆-C₁₀-aryl and alkenyl is C₂-C₆-alkenyl; alkoxyalkyl, where alkoxy is C₁-C₆-alkoxy and alkyl is C₁-C₆-alkyl; CO₂(C₁-C₆-alkyl); CO₂H; CH₂OH;₃

R₄: hydrogen; hydroxy; C₁-C₆-alkyloxy; C₂-C₁₀-alkyloxyalkoxy, where alkyloxy is C₁-C₄ alkyloxy and alkoxy is C₁-C₆-alkyloxy; C₂-C₆-alkenyloxy; C₂-C₆-alkinylxy; C₃-C₁₆-(cyclical saturated group)alkyloxy, where alkyl is C₁-C₆ alkyl; C₄-C₁₆-(cyclical saturated group)alkenyloxy, where alkenyl is C₂-C₆ alkenyl; C₄-C₁₆-(cyclical saturated group)alkinylxy, where alkinyl is C₂-C₆ alkinyl; C₇-C₁₆-arylalkyloxy, where aryl is C₆-C₁₀-aryl and alkyl is C₁-C₆-alkyl; C₈-C₁₆-arylalkenyloxy, where aryl is C₆-C₁₀-aryl and alkenyl is C₂-C₆-alkenyl; C₈-C₁₆-arylalkinylxy, where aryl is C₆-C₁₀-aryl and alkinyl is C₂-C₆-alkinyl; C₁-C₆-alkanoyloxy; C₃-C₆-alkenoyloxy; C₃-C₆-alkinoyloxy; C₇-C₁₆-arylalkanoyloxy, where aryl is C₆-C₁₀-aryl and alkanoyloxy is C₂-C₆-alkanoyloxy; C₉-C₁₆-arylalkenoyloxy, where aryl is C₆-C₁₀-aryl and alkenoyloxy is C₃-C₆-alkenoyloxy; C₉-C₁₆-arylalkinoyloxy, where aryl is C₆-C₁₀-aryl and alkinoyloxy is C₃-C₆-alkinoyloxy;

R₅: hydrogen; hydroxy; C₁-C₆-alkyloxy; C₂-C₁₀-alkyloxyalkoxy, where alkyloxy is C₁-C₄ alkyloxy and alkoxy is C₁-C₆-alkyloxy; C₂-C₆-alkenyoxy; C₂-C₆-alkinyloxy; C₃-C₁₆-(cyclical saturated group)alkyloxy, where alkyl is C₁-C₆ alkyl; C₄-C₁₆-(cyclical saturated group)alkenyoxy, where alkenyl is C₂-C₆ alkenyl; C₄-C₁₆-(cyclical saturated group)alkinyloxy, where alkinyl is C₂-C₆ alkinyl; C₇-C₁₆-arylalkyloxy, where aryl is C₆-C₁₀-aryl and alkyl is C₁-C₆ alkyl; C₈-C₁₆-arylalkenyoxy, where aryl is C₆-C₁₀-aryl and alkenyl is C₂-C₆-alkenyl; C₈-C₁₆-aryalkinyloxy, where aryl is C₆-C₁₀-aryl and alkinyl is C₂-C₆-alkinyl; C₂-C₆-alkanoyloxy; C₇-C₁₆-arylalkanoyloxy, where aryl is C₆-C₁₀-aryl and alkanoyloxy is C₂-C₆-alkanoyloxy;

X is oxygen;

wherein a single or double bond can be present between the carbon atoms of numbers 7 and 8,

wherein alkyl, alkenyl and alkinyl can each be branched or unbranched, aryl can be unsubstituted or mono-, di- or trisubstituted, independently in each case, with hydroxy, halogen, nitro, cyano, thiocyanato, trifluoromethyl, C₁-C₃-alkyl, C₁-C₃-alkoxy, CO₂H, CONH₂, CO₂(C₁-C₃-alkyl), CONH(C₁-C₃-alkyl), CON(C₁-C₃-alkyl)₂, CO(C₁-C₃-alkyl); amino; (C₁-C₃-monoalkyl)amino, (C₁-C₃-dialkyl)amino; C₅-C₆-cycloalkylamino, (C₁-C₃-alkanoyl)amido, SH, SO₃H, SO₃(C₁-C₃-alkyl), SO₂(C₁-C₃-alkyl), SO(C₁-C₃-alkyl), C₁-C₃-alkylthio or C₁-C₃-alkanoylthio,



wherein -(cyclical saturated group) is either preferably C₃-C₁₀-cycloalkyl or a heterocyclic group with 2 to 9 carbon atoms, containing further one or more heteroatoms,

with the exception of compounds where R_1 is methyl, R_2 is C_4 - C_6 -alkyl, R_3 is hydrogen or methyl, R_4 is hydroxy or methoxy and R_5 is hydroxy, methoxy or an oxygen atom bound to the carbon atom in the 5th position,

with the further exception of compounds where R_1 is cyclopropylmethyl and XR_2 is benzyloxy, when R_4 is hydrogen or benzyloxy and R_5 is an oxygen atom bound to the carbon atom in the 5th position; and

with the further exception of compounds where R_1 is cyclopropylmethyl and XR_2 is benzyloxy, when R_4 is hydrogen, hydroxy or benzyloxy and R_5 is hydroxy or methoxy.

2. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier substance and a compound of the formula (IA) or (IAa), and/or a pharmaceutically acceptable acid addition salt thereof,



where the substituents have the following significance:

R₁: C₁-C₆-alkyl; C₂-C₆-alkenyl; C₂-C₆-alkinyl; C₃-C₁₆-(cyclical saturated group)alkyl, where alkyl is C₁-C₆; C₄-C₁₆-(cyclical saturated group)alkenyl, where alkenyl is C₂-C₆; C₄-C₁₆-(cyclical saturated group)alkinyl, where alkinyl is C₂-C₆; C₇-C₁₆-arylalkyl, where aryl is C₆-C₁₀-aryl and alkyl is C₁-C₆-alkyl; C₈-C₁₆-arylalkenyl, where aryl is C₆-C₁₀-aryl and alkenyl is C₂-C₆-alkenyl; C₈-C₁₆-arylalkinyl, where aryl is C₆-C₁₀-aryl and alkinyl is C₂-C₆-alkinyl;

wherein the two substituents R₁ can be the same or different;

R₂: **benzyl**; C₂-alkyl, C₃-alkyl, C₄-alkyl, C₅-alkyl or C₆-alkyl; C₂-C₆-alkenyl; C₂-C₆-alkinyl; C₃-C₁₆-(cyclical saturated group)alkyl, where alkyl is C₁-C₆; C₄-C₁₆-(cyclical saturated group)alkenyl, where alkenyl is C₂-C₆; C₄-C₁₆-(cyclical saturated group)alkinyl, where alkinyl is C₂-C₆; C₇-C₁₆-arylalkyl, where aryl is C₆-C₁₀-aryl and alkyl is C₁-C₆-alkyl; C₈-C₁₆-arylalkenyl, where aryl is C₆-C₁₀-aryl and alkenyl is C₂-C₆-alkenyl; C₈-C₁₆-arylalkinyl, where aryl is C₆-C₁₀-aryl and alkinyl is C₂-C₆-alkinyl; C₃-C₆-alkenoyl; C₃-C₆-alkinoyl; C₉-C₁₆-arylalkenoyl, where aryl is C₆-C₁₀-aryl and alkenoyl is C₃-C₆-alkenoyl; C₉-C₁₆-arylalkinoyl, where aryl is C₆-C₁₀-aryl and alkinoyl is C₃-C₆-alkinoyl;

R₃: hydrogen, C₁-C₆-alkyl; C₂-C₆-alkenyl; C₇-C₁₆-arylalkyl, where aryl is C₆-C₁₀-aryl and alkyl is C₁-C₆-alkyl; C₈-C₁₆-arylalkenyl, where aryl is C₆-C₁₀-aryl and alkenyl is C₂-C₆-alkenyl; alkoxyalkyl, where alkoxy is C₁-C₆-alkoxy and alkyl is C₁-C₆-alkyl; CO₂(C₁-C₆-alkyl); CO₂H; CH₂OH;₃

R₄: hydrogen; hydroxy; C₁-C₆-alkyloxy; C₂-C₁₀-alkyloxyalkoxy, where alkyloxy is C₁-C₄ alkyloxy and alkoxy is C₁-C₆-alkyloxy; C₂-C₆-alkenyloxy; C₂-C₆-alkinyloxy; C₃-C₁₆-(cyclical saturated group)alkyloxy, where alkyl is C₁-C₆ alkyl; C₄-C₁₆-(cyclical saturated group)alkenyloxy, where alkenyl is C₂-C₆ alkenyl; C₄-C₁₆-(cyclical saturated group)alkinyloxy where alkinyl is C₂-C₆ alkinyl; C₇-C₁₆-arylalkyloxy, where aryl is C₆-C₁₀-aryl and alkyl is C₁-C₆-alkyl; C₈-C₁₆-arylalkenyloxy, where aryl is C₆-C₁₀-aryl and alkenyl is C₂-C₆-alkenyl; C₈-C₁₆-arylalkinyloxy, where aryl is C₆-C₁₀-aryl and alkinyl is C₂-C₆-alkinyl; C₂-C₆-alkanoyloxy; C₃-C₆-alkenoyloxy; C₃-C₆-alkinoyloxy; C₈-C₁₆-arylalkanoyloxy, where aryl is C₆-C₁₀-aryl and alkanoyloxy is C₂-C₆-alkanoyloxy; C₉-C₁₆-arylalkenoyloxy, where aryl is C₆-C₁₀-aryl and alkenoyloxy is C₃-C₆-alkenoyloxy; C₉-C₁₆-arylalkinoyloxy, where aryl is C₆-C₁₀-aryl and alkinoyloxy is C₃-C₆-alkinoyloxy;

R₅: hydrogen; hydroxy; C₁-C₆-alkyloxy; C₂-C₁₀-alkyloxyalkoxy, where alkyloxy is C₁-C₄ alkyloxy and alkoxy is C₁-C₆-alkyloxy; C₂-C₆-alkenyloxy; C₂-C₆-alkinyloxy; C₃-C₁₆-(cyclical saturated group)alkyloxy, where alkyl is C₁-C₆ alkyl; C₄-C₁₆-(cyclical saturated group)alkenyloxy, where alkenyl is C₂-C₆ alkenyl; C₄-C₁₆-(cyclical saturated group)alkinyloxy, where alkinyl is C₂-C₆ alkinyl; C₇-C₁₆-arylalkyloxy, where aryl is C₆-C₁₀-aryl and alkyl is C₁-C₆-alkyl; C₈-C₁₆-arylalkenyloxy, where aryl is C₆-C₁₀-aryl and alkenyl is C₂-C₆-alkenyl; C₈-C₁₆-arylalkinyloxy, where aryl is C₆-C₁₀-aryl and alkinyl is C₂-C₆-alkinyl; C₂-C₆-alkanoyloxy; C₇-C₁₆-arylalkanoyloxy, where aryl is C₆-C₁₀-aryl and alkanoyloxy is C₂-C₆-alkanoyloxy;

X is oxygen;

Y' is Γ , Br^- , Cl^- , OH^- or another pharmacologically acceptable counterion;

wherein a single or double bond can be present between the carbon atoms of numbers 7 and 8,

wherein alkyl, alkenyl and alkinyl can each be branched or unbranched, aryl can be unsubstituted or mono-, di- or trisubstituted, independently in each case, with hydroxy, halogen, nitro, cyano, thiocyanato, trifluoromethyl, $\text{C}_1\text{-C}_3$ -alkyl, $\text{C}_1\text{-C}_3$ -alkoxy, CO_2H , CONH_2 , $\text{CO}_2(\text{C}_1\text{-C}_3\text{-alkyl})$, $\text{CONH}(\text{C}_1\text{-C}_3\text{-alkyl})$, $\text{CON}(\text{C}_1\text{-C}_3\text{-alkyl})_2$, $\text{CO}(\text{C}_1\text{-C}_3\text{-alkyl})$; amino; $(\text{C}_1\text{-C}_3\text{-monoalkyl})\text{amino}$, $(\text{C}_1\text{-C}_3\text{-dialkyl})\text{amino}$; $\text{C}_5\text{-C}_6$ -cycloalkylamino, $(\text{C}_1\text{-C}_3\text{-alkanoyl})\text{amido}$, SH , SO_3H , $\text{SO}_3(\text{C}_1\text{-C}_3\text{-alkyl})$, $\text{SO}_2(\text{C}_1\text{-C}_3\text{-alkyl})$, $\text{SO}(\text{C}_1\text{-C}_3\text{-alkyl})$, $\text{C}_1\text{-C}_3\text{-alkylthio}$ or $\text{C}_1\text{-C}_3\text{-alkanoylthio}$,
wherein -(cyclical saturated group) is either preferably $\text{C}_3\text{-C}_{10}$ -cycloalkyl or a heterocyclical group with 2 to 9 carbon atoms, containing furthermore one or more heteroatoms.

3. (Previously Presented) A composition of claim 1 or 2, wherein for the compound of formula (I) or (IA), R_1 is $\text{C}_1\text{-C}_6$ -alkyl; $\text{C}_2\text{-C}_6$ -alkenyl; $\text{C}_4\text{-C}_{16}$ -cycloalkylalkyl, where cycloalkyl is $\text{C}_3\text{-C}_{10}$ cycloalkyl and alkyl is $\text{C}_1\text{-C}_6$ alkyl; $\text{C}_7\text{-C}_{16}$ -arylalkyl, where aryl is $\text{C}_6\text{-C}_{10}$ -aryl and alkyl is $\text{C}_1\text{-C}_6$ -alkyl; R_2 is $\text{C}_8\text{-C}_{16}$ -arylalkyl, where aryl is $\text{C}_6\text{-C}_{10}$ -aryl and alkyl is $\text{C}_1\text{-C}_6$ -alkyl; C_8 -arylklenyl or $\text{C}_{10}\text{-C}_{16}$ -arylklenyl, where aryl is $\text{C}_6\text{-C}_{10}$ -aryl and alkenyl is $\text{C}_2\text{-C}_6$ -alkenyl; R_3 is hydrogen or methyl; R_4 is hydroxy, methoxy or acetoxy.

4. (Previously Presented) A composition of claim 2, wherein for the compound of formula (IA), R₁ is C₁-C₆-alkyl; C₂-C₆-alkenyl; C₄-C₁₆-cycloalkylalkyl, where cycloalkyl is C₃-C₁₀ cycloalkyl and alkyl is C₁-C₆ alkyl; C₇-C₁₆-arylalkyl, where aryl is C₆-C₁₀-aryl and alkyl is C₁-C₆-alkyl; R₂ is C₂-C₆-alkyl or C₂-C₆-alkenyl, R₃ is hydrogen or methyl; R₄ is hydroxy, methoxy or acetoxy.

5. (Currently Amended) A composition of claim 1 or 2, wherein the compound is selected from:

17-allyl-4,5 α -epoxy-3-methoxy-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5 α -epoxy-3-hydroxy-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5 α -epoxy-3-methoxy-5 β -methyl-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5 α -epoxy-3-hydroxy-5 β -methyl-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5 α -epoxy-3-methoxy-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5 α -epoxy-3-hydroxy-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5 α -epoxy-3-methoxy-5 β -methyl-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5 α -epoxy-3-methoxy-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5 α -epoxy-3-hydroxy-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5 α -epoxy-3-hydroxy-5 β -methyl-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5 α -epoxy-3-methoxy-5 β -methyl-14 β -(3-phenylpropyloxy)morphinan-6-one, 4,5 α -epoxy-3-methoxy-5 β ,17-dimethyl-14 β -[(3-phenylpropyl)oxy]morphinan-6-one, 4,5 α -epoxy-3-hydroxy-5 β ,17-dimethyl-14 β -[(3-phenylpropyl)oxy]morphinan-6-one, 17-propyl-4,5 α -epoxy-3-methoxy-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-propyl-4,5 α -epoxy-3-hydroxy-14 β -(3-

phenylpropyloxy)morphinan-6-one, 17-propyl-4,5 α -epoxy-3-methoxy-5 β -methyl-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-propyl-4,5 α -epoxy-3-hydroxy-5 β -methyl-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5 α -epoxy-3-methoxy-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5 α -epoxy-3-hydroxy-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5 α -epoxy-3-methoxy-5 β -methyl-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5 α -epoxy-3-hydroxy-5 β -methyl-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5 α -epoxy-3-methoxy-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5 α -epoxy-3-hydroxy-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5 α -epoxy-3-methoxy-5 β -methyl-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5 α -epoxy-3-hydroxy-5 β -methyl-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5 α -epoxy-3-methoxy-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5 α -epoxy-3-hydroxy-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5 α -epoxy-3-methoxy-5 β -methyl-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5 α -epoxy-3-hydroxy-5 β -methyl-14 β -(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5 α -epoxy-3-hydroxy-14 β -[(2-methylbenzyl)oxy]morphinan-6-one, 14 β [(2-chlorobenzyl)oxy]-17-(cyclopropylmethyl)-4,5 α -epoxy-3-hydroxymorphinan-6-one, 14 β -benzyloxy-17-cyclopropylmethyl-4,5 α -epoxy-3-hydroxymorphinan-6-one, 14 β -butoxy-17-cyclopropylmethyl-4,5 α -epoxy-3-hydroxymorphinan-6-one, 17-cyclopropylmethyl-4,5 α -epoxy-3-hydroxy-14 β [(3-methylbutyl)oxy]morphinan-6-one, 4,5 α -epoxy-5 β ,17-dimethyl-14 β [(3-phenylpropyl)oxy]-3-[(prop-2-inyl)oxy]morphinan-6-one, 14 β [(3-chlorobenzyl)oxy]-4,5 α -epoxy-17-methyl-3-[(prop-2-inyl)oxy]morphinan-6-one, 4,5 α -epoxy-17-ethyl-3-methoxy-14 β [(3-phenylpropyl)oxy]morphinan-6-one, 4,5 α -epoxy-17-ethyl-3-hydroxy-14 β [(3-phenylpropyl)oxy]morphinan-6-one, 4,5 α -epoxy-3-hydroxy-14 β [(3-

methylbutyl)oxy]-17-propylmorphinan-6-one, 5β -benzyl-14-methoxycodeinone ($=$ 5-benzyl-7,8-didehydro-4,5 α -epoxy-3,14 β -dimethoxy-17-methyl-morphinan-6-one), 5β -benzyl-4,5 α -epoxy-3,14 β -dimethoxy-17-methylmorphinan-6-one, 5β -benzyl-4,5 α -epoxy-3-hydroxy-14 β -methoxy-17-methylmorphinan-6-one, 4-hydroxy-3-methoxy-17-methyl-14-[(3-phenylpropyl)oxy]-morphinan-6-one, 3,4-dimethoxy-17-methyl-14-[(3-phenylpropyl)oxy]-morphinan-6-one, 14 β -benzyloxy-3,4-dimethoxy-17-methylmorphinan-6-one, 14 β -benzyloxy-3,4-dimethoxy-17-methylmorphinan-6-one, 4-hydroxy-3-methoxy-17-methyl-14 β -[(2-naphthylmethyl)oxy]morphinan-6-one, 3,4-dimethoxy-17-methyl-14 β -[(2-naphthylmethyl)oxy]morphinan-6-one, 4-hydroxy-3-methoxy-5 β ,17-dimethyl-14 β -[(3-phenylpropyl)oxy]-morphinan-6-one, 3,4-dimethoxy-5 β ,17-dimethyl-14 β -[(3-phenylpropyl)oxy]-morphinan-6-one, 14 β -ethoxy-4-hydroxy-3-methoxy-5 β ,17-dimethylmorphinan-6-one, 14 β -ethoxy-3,4-dimethoxy-5 β ,17-dimethylmorphinan-6-one, 4,5 α -epoxy-3-hydroxy-17,17-dimethyl-6-oxo-14 β -[(3-phenylpropyl)oxy]morphinan-iodide, (17S)-4,5 α -epoxy-17-ethyl-3-hydroxy-17-methyl-6-oxo-14 β -[(3-phenylpropyl)oxy]morphinan-iodide, (17R)-4,5 α -epoxy-3-hydroxy-17-methyl-6-oxo-14 β -[(3-phenylpropyl)oxy]-17-[(2(R,S)-tetrahydrofuran-2-yl)methyl]morphinan-iodide, (17R)-17-allyl-4,5 α -epoxy-14 β -ethoxy-3-hydroxy-17-methyl-6-oxomorphinan-iodide, (17R)-17-allyl-4,5 α -epoxy-3-hydroxy-14 β -methoxy-17-methyl-6-oxomorphinan-iodide, (17S)-17-allyl-4,5 α -epoxy-3-hydroxy-14 β -methoxy-17-methyl-6-oxomorphinan-iodide, 4,5 α -epoxy-3-hydroxy-14 β -methoxy-17,17-dimethyl-6-oxomorphinan-iodide, 5 β -benzyl-14 β -(butyloxy)-4,5-epoxy-3-hydroxy-17,17-dimethyl-6-oxomorphinan-iodide, (17S)-17-allyl-5 β -benzyl-14 β -butoxy-4,5 α -epoxy-3-hydroxy-17-methyl-6-oxomorphinan-iodide, 14 β -butoxy-4,5 α -epoxy-3-hydroxy-17,17-dimethyl-6-

oxomorphinanium-iodide, (17R)-17-cyclopropylmethyl-4,5 α -epoxy-3-hydroxy-17-methyl-6-oxo-14 β -[(3-phenylpropyl)oxy]morphinanium-iodide, (17R)-17-cyclopropylmethyl-4,5 α -epoxy-3-methoxy-17-methyl-6-oxo-14 β -[(3-phenylpropyl)oxy]morphinanium-iodide, (17R)-17-cyclopropylmethyl-4,5 α -epoxy-3-hydroxy-17-methyl-6-oxo-14 β -[(2-phenylbenzyl)oxy]morphinanium-iodide, (17R)-14 β -[(4-chlorobenzyl)oxy]-17-cyclopropylmethyl-4,5 α -epoxy-3-hydroxy-17-methyl-6-oxo-14 β -[(2-phenylethyl)morphinanium-iodide, 4,5 α -epoxy-3-methoxy-17-methyl-14 β -[(3-phenylpropyl)oxy]morphinan-6-one, 4,5 α -epoxy-3-methoxy-14 β -[(3-phenylpropyl)oxy]morphinan-6-one, 4,5 α -epoxy-3-hydroxy-17-methyl-14 β -[(3-phenylpropyl)oxy]morphinan-6-one, 4,5 α -epoxy-17-methyl-14 β -[(3-phenylpropyl)oxy]morphinan-6-one, 17-(cyclopropylmethyl)-4,5 α -epoxy-14 β -[(3-phenylpropyl)oxy]morphinan-6-one, 4,5 α -epoxy-14 β -[(3-phenylpropyl)oxy]morphinan-6-one, 17-(cyclopropylmethyl)-4-hydroxy-14 β -[(3-phenylpropyl)oxy]morphinan-6-one, 17-(cyclopropylmethyl)-4-methoxy-14 β -[(3-phenylpropyl)oxy]morphinan-6-one, 4-(n-butyloxy)-17-(cyclopropylmethyl)-14 β -[(3-phenylpropyl)oxy]morphinan-6-one, and a pharmaceutically acceptable salt thereof.

Claim 6. (Cancelled)

Claim 7. (Cancelled).

8. (Previously Presented) A method of treating pain, comprising the step of administering to a patient in need thereof an effective amount of the composition of claim 1 or 2.

9. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R₅ is OH or alkyloxy.

10. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R₃ is hydrogen, alkyl or aralkyl.

11. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R₄ is OH, alkyloxy, alkenyloxy or alkinyloxy.

12. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, a single bond is present between carbon atom numbers 7 and 8.

13. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R₂ is alkyl or aralkyl.

14. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R₁ is alkyl, (cyclical saturated group)alkyl, aralkyl or alkenyl.

15. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R₁ is C₁-C₆-alkyl; C₂-C₆-alkenyl; C₂-C₆-alkinyl; C₃-C₁₆-(cyclical saturated

group)alkyl, where alkyl is C₁-C₆ alkyl; C₄-C₁₆-(cyclical saturated group)alkenyl, where alkenyl is C₂-C₆ alkenyl; C₄-C₁₆-(cyclical saturated group)alkinyl, where alkinyl is C₂-C₆ alkinyl; C₇-C₁₆-arylalkyl, where aryl is C₆-C₁₀-aryl and alkyl is C₁-C₆-alkyl; C₈-C₁₆-arylalkenyl, where aryl is C₆-C₁₀-aryl and alkenyl is C₂-C₆-alkenyl; C₈-C₁₆-arylalkinyl, where aryl is C₆-C₁₀-aryl and alkinyl is C₂-C₆-alkinyl.

16. (Previously Presented) A composition according to claim 10, wherein in the compound, R₃ is hydrogen or alkyl.

17. (Previously Presented) A composition according to claim 13, wherein in the compound, R₂ is aralkyl.

18. (New) A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier substance and (ii) a compound and/or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:

14 β -[(2-chlorobenzyl)oxy]-17-(cyclopropylmethyl)-4,5 α -epoxy-3-hydroxymorphinan-6-one, 14 β -benzyloxy-17-cyclopropylmethyl-4,5 α -epoxy-3-hydroxymorphinan-6-one, 17-cyclopropylmethyl-4,5 α -epoxy-3-hydroxy-14 β -[(3-methylbutyl)oxy]morphinan-6-one, 14 β -[(3-chlorobenzyl)oxy]-4,5 α -epoxy-17-methyl-3-[(prop-2-inyl)oxy]morphinan-6-one, 5 β -benzyl-14-methoxycodeinone (= 5-benzyl-7,8-didehydro-4,5 α -epoxy-3,14 β -dimethoxy-17-methyl-morphinan-6-one), 5 β -benzyl-4,5 α -epoxy-3,14 β -dimethoxy-17-methylmorphinan-6-one, 5 β -benzyl-4,5 α -epoxy-3-hydroxy-14 β -methoxy-17-methylmorphinan-6-one, 14 β -benzyloxy-4-hydroxy-3-methoxy-17-methylmorphinan-6-one, 14 β -benzyloxy-3,4-dimethoxy-17-

methylmorphinan-6-one, 14 β -ethoxy-4-hydroxy-3-methoxy-5 β ,17-dimethylmorphinan-6-one, 14 β -ethoxy-3,4-dimethoxy-5 β ,17-dimethylmorphinan-6-one, 14 β -benzyloxy-3,4-dimethoxy-5 β ,17-dimethylmorphinan-6-one, (17R)-17-allyl-4,5 α -epoxy-14 β -ethoxy-3-hydroxy-17-methyl-6-oxomorphinanium-iodide, (17R)-17-allyl-4,5 α -epoxy-3-hydroxy-14 β -methoxy-17-methyl-6-oxomorphinanium-iodide, (17S)-17-allyl-4,5 α -epoxy-3-hydroxy-14 β -methoxy-17-methyl-6-oxomorphinanium-iodide, 4,5 α -epoxy-3-hydroxy-14 β -methoxy-17,17-dimethyl-6-oxomorphinanium-iodide, (17R)-14 β -[(4-chlorobenzyl)oxy]-17-cyclopropylmethyl-4,5 α -epoxy-3-hydroxy-17-methyl-6-oxomorphinanium-iodide and 17(R)-4,5 α -epoxy-3-hydroxy-14 β -methoxy-17-methyl-6-oxo-17-(2-phenylethyl)morphinanium-iodide.